Status:
COMPLETED
Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation
Lead Sponsor:
University of Utah
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
This study will evaluate the application of hAM at the time of cardiac surgery to decrease inflammation and the subsequent substrate to reduce incidence of post-operative atrial fibrillation. Patients...
Eligibility Criteria
Inclusion
- Patients undergoing primary elective CABG at the University of Utah Hospital
- Ability to provided informed consent and follow-up with protocol procedures
Exclusion
- Patients in AF at the time of surgery
- Prior history of sternotomy
- Prior history of pericarditis
- Currently on aggressive antiarrhythmic therapy (does not include beta blockers)
- Patients with an implantable cardiac device (pacemaker, ICD, CRT-D)
- Ejection fraction \<45%
Key Trial Info
Start Date :
October 11 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2021
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT04130061
Start Date
October 11 2019
End Date
June 1 2021
Last Update
December 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Utah
Salt Lake City, Utah, United States, 84132